#European #Medicines Agency (EMA) Accepts BioMarin's #Marketing Application for Pegvaliase MAA for #Treatment of Phenylketonuria (PKU)

#European #Medicines Agency (EMA) Accepts BioMarin's #Marketing Application for Pegvaliase MAA for #Treatment of Phenylketonuria (PKU)







March 28, 2018 /PRNewswire/ — BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today that the European Medicines Agency (EMA) has accepted BioMarin’s submission of a Marketing Authorization … from a page on the website of the European Society …






Leave a Reply

Your email address will not be published. Required fields are marked *